Aktis Oncology, Inc.(AKTS)
Pharmaceuticals
Radiopharmaceuticals
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership changeShares owned | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-21 | Herrmann Ken Director | Sale | -4,856 | -6.74%67,182 | $24.56 | $119,274 | View SEC filing | |
| 2026-07-20 | Herrmann Ken Director | Sale | -3,065 | -4.08%72,038 | $25.21 | $77,259 | View SEC filing | |
| 2026-07-10 | Ron-Bigger Shulamit Chief Operating Officer | Sale | -50,000 | -100.00%0 | $27.75 | $1,387,558 | View SEC filing | |
| 2026-07-10 | Czibere Akos Chief Medical Officer | Sale | -50,000 | -40.06%74,805 | $27.77 | $1,388,701 | View SEC filing | |
| 2026-01-14 | Foley Todd Director, 10% Owner | Purchase | +232,870 | +5.82%4,235,403 | $18.00 | $4,191,660 | View SEC filing | |
| 2026-01-14 | EVNIN LUKE 10% Owner | Purchase | +1,112,777 | +12.17%10,260,064 | $18.00 | $20,029,986 | View SEC filing | |
| 2026-01-14 | GADICKE ANSBERT 10% Owner | Purchase | +1,112,777 | +12.17%10,260,064 | $18.00 | $20,029,986 | View SEC filing | |
| 2026-01-12 | Vida Ventures II, LLC 10% Owner | Purchase | +835,000 | -96.76%157,387 | $18.00 | $15,030,000 | View SEC filing | |
| 2026-01-12 | Kim Helen Susan Director, 10% Owner | Purchase | +835,000 | +16.72%5,829,212 | $18.00 | $15,030,000 | View SEC filing | |
| 2026-01-12 | NODELMAN OLEG Director | Purchase | +2,222,222 | -84.71%347,305 | $18.00 | $39,999,996 | View SEC filing |
1-10 of 10